Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease

Xingye Xu, Fangping Ding, Xiangqi Hu, Fan Yang, Ting Zhang, Jie Dong, Ying Xue, Tao Liu, Jing Wang, Qi JinFrontiers in Microbiology 2023 · DOI

Abstract

Our study deepened our understanding of the respiratory tract mycobiome in some diseases that are less studied and identified the commonalities and differences among different kinds of pulmonary disease. These results would provide the solid basis for further investigation of the association between the mycobiome and pathogenicity of pulmonary diseases.

Introduction

While the bacterial landscape of the human lungs has been extensively mapped, the fungal component—the "mycobiome"—remains a relatively unexplored frontier. Fungi are potent triggers for inflammation and opportunistic infections, yet their role in chronic and acute respiratory conditions is poorly understood. This study addresses a critical gap in respiratory medicine: determining whether the fungal landscape of the upper respiratory tract changes predictably across various lung diseases. By sampling the oropharynx, researchers aimed to identify if non-invasive swabs could reflect the pathological state of the lungs in patients with Interstitial Lung Disease (ILD), Bacterial Pneumonia (BP), Fungal Pneumonia (FP), Asthma (AS), and Lung Cancer (LC).

Methods

The study analyzed oropharyngeal swabs (OS) from a cohort of 75 individuals, including 65 patients across five disease groups (ILD: 20, BP: 14, FP: 11, AS: 8, LC: 12) and 10 healthy controls (HC). To ensure data integrity, sterile water samples were used as negative controls to account for reagent contamination.

The researchers employed a targeted metagenomic approach:

  • Sequencing: The Internal Transcribed Spacer 2 (ITS2) region, a standard barcode for fungal identification, was amplified and sequenced using high-throughput Illumina technology.
  • Bioinformatics: Sequences were clustered into Operational Taxonomic Units (OTUs) and taxonomically assigned using the UNITE database.
  • Statistical Analysis: Alpha diversity (within-sample richness) and Beta diversity (between-group differences) were calculated.
  • Biomarker Discovery: Linear Discriminant Analysis Effect Size (LEfSe) was used to identify characterizing taxa, and Receiver Operating Characteristic (ROC) curves were generated to evaluate the diagnostic potential of these fungal markers.

Results

The Dominance of Malassezia

A primary finding of the study was the overwhelming presence of the genus Malassezia across all groups. While typically associated with skin flora, Malassezia accounted for approximately 23.5% of the mycobiome in healthy individuals. However, in diseased states, this proportion surged to between 46% and 72%, suggesting that the altered environment of a "sick" respiratory tract provides a niche where Malassezia can outcompete other commensal fungi.

Figure 1: The top 15 most abundant genera on average for all disease groups and healthy controls.

Diversity and Disease-Specific Markers

The study revealed significant shifts in fungal diversity and composition:

  • Increased Richness: Patients with ILD, BP, and FP exhibited significantly higher fungal richness (Chao1 index) compared to healthy controls. Asthma patients, conversely, showed diversity levels more similar to the healthy group.
  • Diagnostic Accuracy: ROC analysis demonstrated high sensitivity and specificity for distinguishing disease from health. The Area Under the Curve (AUC) reached 0.92 for Lung Cancer and 0.85 for Bacterial Pneumonia.
  • Specific Taxa:
    • ILD was characterized by Schizophyllum commune.
  • Lung Cancer showed enrichment in Penicillium and Malassezia restricta.
  • Fungal Pneumonia was uniquely marked by the genus Pyrenophora.
  • Healthy Controls surprisingly had higher abundances of Candida and Aspergillus, suggesting these may act as harmless commensals in a healthy state before being displaced during disease.

Clinical and Environmental Correlations

The researchers identified correlations between specific fungi and lung function (FEV1/FVC ratios). For instance, P. solitum was negatively correlated with lung function in asthma and fungal pneumonia patients. Additionally, the presence of Knufia—a genus typically found on rock surfaces—in all disease groups but its near-absence in healthy controls suggests an unexplored role in human pathology. Dietary signals were also noted, with Flammulina velutipes (Enoki mushroom) found exclusively in healthy controls.

Discussion

This pilot study highlights the potential of the oropharyngeal mycobiome as a non-invasive diagnostic tool. The identified fungal "fingerprints" offer a promising avenue for biomarker development, particularly for conditions like lung cancer where early detection is critical.

However, several limitations remain. The sample size is relatively small, necessitating validation in larger, more diverse cohorts. Furthermore, while oropharyngeal swabs are accessible, they may not perfectly represent the environment of the lower respiratory tract. Future research should focus on the "inter-kingdom" interactions between fungi and bacteria and determine whether these mycobiome shifts are a cause or a consequence of pulmonary disease progression.

Conclusion

By identifying commonalities and differences in the mycobiome across various pulmonary diseases, this study provides a foundational basis for investigating the pathogenicity of fungi in the respiratory tract. The dominance of Malassezia and the discovery of disease-specific markers underscore the importance of including the mycobiome in future respiratory research.

Summary updated

Abstract

Our study deepened our understanding of the respiratory tract mycobiome in some diseases that are less studied and identified the commonalities and differences among different kinds of pulmonary disease. These results would provide the solid basis for further investigation of the association between the mycobiome and pathogenicity of pulmonary diseases.
BibTeX
@inproceedings{xu2023upper,
  author = {Xingye Xu and Fangping Ding and Xiangqi Hu and Fan Yang and Ting Zhang and Jie Dong and Ying Xue and Tao Liu and Jing Wang and Qi Jin},
  title = {{Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease}},
  booktitle = {Frontiers in Microbiology},
  year = {2023},
  doi = {10.3389/fmicb.2023.1117779},
}
Figure